107 related articles for article (PubMed ID: 38428703)
1. CD39
Shen Y; Qiu Y; Duan ZQ; Li YX; Wang Y; Zhang YY; Zhu BH; Yu XH; Tan XL; Chen W; Zhuang Y; Zou QM; Ma DY; Peng LS
Pharmacol Res; 2024 Apr; 202():107122. PubMed ID: 38428703
[TBL] [Abstract][Full Text] [Related]
2. CD39 expression defines exhausted CD4
Duan ZQ; Li YX; Qiu Y; Shen Y; Wang Y; Zhang YY; Zhu BH; Yu XH; Tan XL; Chen W; Zhuang Y; Cheng P; Zhang WJ; Zou QM; Ma DY; Peng LS
Clin Transl Immunology; 2024; 13(3):e1499. PubMed ID: 38501063
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of tumor-reactive CD4
Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
[TBL] [Abstract][Full Text] [Related]
4. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL
Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514
[TBL] [Abstract][Full Text] [Related]
5. The ectonucleotidase CD39 identifies tumor-reactive CD8
Chow A; Uddin FZ; Liu M; Dobrin A; Nabet BY; Mangarin L; Lavin Y; Rizvi H; Tischfield SE; Quintanal-Villalonga A; Chan JM; Shah N; Allaj V; Manoj P; Mattar M; Meneses M; Landau R; Ward M; Kulick A; Kwong C; Wierzbicki M; Yavner J; Egger J; Chavan SS; Farillas A; Holland A; Sridhar H; Ciampricotti M; Hirschhorn D; Guan X; Richards AL; Heller G; Mansilla-Soto J; Sadelain M; Klebanoff CA; Hellmann MD; Sen T; de Stanchina E; Wolchok JD; Merghoub T; Rudin CM
Immunity; 2023 Jan; 56(1):93-106.e6. PubMed ID: 36574773
[TBL] [Abstract][Full Text] [Related]
6. Adenosine Generated by Regulatory T Cells Induces CD8
Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
[TBL] [Abstract][Full Text] [Related]
7. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39
Leem G; Park J; Jeon M; Kim ES; Kim SW; Lee YJ; Choi SJ; Choi B; Park S; Ju YS; Jung I; Kim S; Shin EC; Lee JY; Park SH
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335029
[TBL] [Abstract][Full Text] [Related]
8. Genetically driven CD39 expression shapes human tumor-infiltrating CD8
Gallerano D; Ciminati S; Grimaldi A; Piconese S; Cammarata I; Focaccetti C; Pacella I; Accapezzato D; Lancellotti F; Sacco L; Caronna R; Melaiu O; Fruci D; D'Oria V; Manzi E; Sagnotta A; Parrino C; Coletta D; Peruzzi G; Terenzi V; Battisti A; Cassoni A; Fadda MT; Brozzetti S; Fazzi K; Grazi GL; Valentini V; Chirletti P; Polimeni A; Barnaba V; Timperi E
Int J Cancer; 2020 Nov; 147(9):2597-2610. PubMed ID: 32483858
[TBL] [Abstract][Full Text] [Related]
9. IL-12 and IL-27 Promote CD39 Expression on CD8+ T Cells and Differentially Regulate the CD39+CD8+ T Cell Phenotype.
Gerhardt L; Hong MMY; Yousefi Y; Figueredo R; Maleki Vareki S
J Immunol; 2023 May; 210(10):1598-1606. PubMed ID: 37000461
[TBL] [Abstract][Full Text] [Related]
10. Immune profiling identifies CD8
Chen Z; Guo ML; Li YY; Yan K; Li L; Shen F; Guan H; Liu QZ; Xu B; Lian ZX
Front Immunol; 2022; 13():894919. PubMed ID: 36420264
[TBL] [Abstract][Full Text] [Related]
11. [The regulatory function of tumor-infiltrating Th9 cells to anti-tumor activity of CD8(+) T cells in patients with gastric cancer].
Sun PS; Gao ZJ; Fan LX; Liu YF; Chen BH; Mu SZ; Yan ZQ
Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1186-1193. PubMed ID: 36380667
[No Abstract] [Full Text] [Related]
12. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
Duhen T; Duhen R; Montler R; Moses J; Moudgil T; de Miranda NF; Goodall CP; Blair TC; Fox BA; McDermott JE; Chang SC; Grunkemeier G; Leidner R; Bell RB; Weinberg AD
Nat Commun; 2018 Jul; 9(1):2724. PubMed ID: 30006565
[TBL] [Abstract][Full Text] [Related]
13. Increased tumor-infiltrating CD45RA
Mao FY; Kong H; Zhao YL; Peng LS; Chen W; Zhang JY; Cheng P; Wang TT; Lv YP; Teng YS; Fu XL; Liu YG; Wu XL; Hao CJ; You N; Luo P; Yu PW; Zou QM; Guo G; Zhuang Y
Cell Death Dis; 2017 Aug; 8(8):e3002. PubMed ID: 28817117
[TBL] [Abstract][Full Text] [Related]
14. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of CD39 and high tumoral CD39⁺/CD8⁺ ratio are associated with adverse prognosis in resectable gastric cancer.
Cai XY; Wang XF; Li J; Dong JN; Liu JQ; Li NP; Yun B; Xia RL
Int J Clin Exp Pathol; 2015; 8(11):14757-64. PubMed ID: 26823801
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of low avidity tumor-specific CD8
Sugiyarto G; Lau D; Hill SL; Arcia-Anaya D; Boulanger DSM; Parkes E; James E; Elliott T
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586767
[TBL] [Abstract][Full Text] [Related]
17. CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden.
van den Bulk J; van der Ploeg M; Ijsselsteijn ME; Ruano D; van der Breggen R; Duhen R; Peeters KCMJ; Fariña-Sarasqueta A; Verdegaal EME; van der Burg SH; Duhen T; de Miranda NFCC
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36792124
[TBL] [Abstract][Full Text] [Related]
18. Reversal of the CD8
Li J; Huang HH; Tu B; Zhou MJ; Hu W; Fu YL; Li XY; Yang T; Song JW; Fan X; Jiao YM; Xu RN; Zhang JY; Zhou CB; Yuan JH; Zhen C; Shi M; Wang FS; Zhang C
Front Immunol; 2021; 12():687296. PubMed ID: 34177939
[TBL] [Abstract][Full Text] [Related]
19. CD226 identifies functional CD8
Huang H; Huang Z; Ge J; Yang J; Chen J; Xu B; Wu S; Zheng X; Chen L; Zhang X; Jiang J
Front Immunol; 2023; 14():1150803. PubMed ID: 37056782
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer.
Qiao M; Zhou F; Liu X; Jiang T; Wang H; Jia Y; Li X; Zhao C; Cheng L; Chen X; Ren S; Liu H; Zhou C
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
